Target

TBK1/IKKε

Halting the Inflammation Process

• KO mouse protected from hepatic steatosis on HFD
• Inhibitor lowers liver cholesterol and triglycerides in mouse in vivo model
• Inhibitor decreases liver enzymes in several NASH models
• IST POC trial with known inhibitor confirms liver fat loss
• Documented human safety for this target
• Implicated as I/O approach to cancer
• Active site SBDD enabled